Diadema Partners’s ProQR Therapeutics PRQR Stock Holding History

Diadema Partners’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$292K	Buy	180,083 +12,551	+7%	+$20.6K	0.05%	120
2025 Q4	$338K	Buy	167,532 +9,838	+6%	+$23K	0.06%	123
2025 Q3	$336K	Hold	157,694	–	–	0.09%	105
2025 Q2	$322K	Sell	157,694 -50,000	-24%	-$81.3K	0.1%	84
2025 Q1	$276K	Buy	207,694 +49,671	+31%	+$106K	0.07%	90
2024 Q4	$419K	Buy	+158,023	New	+$502K	0.18%	75

Other funds holding PRQR

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PFM

Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Diadema Partners's PRQR Position: Q1 2026 in Review

Diadema Partners increased its ProQR Therapeutics (PRQR) stake by 7.5% in Q1 2026, buying an estimated $20.6K and bringing the position to 180,083 shares worth $292K. The position accounts for 0.05% of the portfolio, ranked #120.

Diadema Partners first reported a position in PRQR in Q4 2024 and has held it in 6 quarters since. The position peaked at $419K in Q4 2024. 69 funds tracked by Wall St. Rank hold PRQR as of Q1 2026.

Diadema Partners held 180,083 shares of ProQR Therapeutics worth $292K as of Q1 2026.
Diadema Partners bought 12,551 ProQR Therapeutics shares in Q1 2026, an estimated $20.6K.
ProQR Therapeutics made up 0.05% of Diadema Partners's portfolio in Q1 2026, its #120 holding.
Diadema Partners first reported a position in ProQR Therapeutics in Q4 2024 and has held it in 6 quarters since.
Diadema Partners's ProQR Therapeutics position peaked at $419K in Q4 2024.
69 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2026.

Based on Diadema Partners's 13F filing for Q1 2026, filed 15 May 2026.